This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Prion protein (PRNP; PrP; CD230)	Rat studies suggest the humanized anti-PrP antibody PRN100 could help treat AD. In rats, intracardiac injection of PRN100 decreased β-amyloid–associated disruption of long-term potentiation in neurons compared with injection of an isotype control antibody. Next steps include clinical trials of PRN100 in patients with sporadic Creutzfeldt-Jakob disease (CJD), which is caused by abnormal PrP. *SciBX* 7(21); doi:10.1038/scibx.2014.618 Published online May 29, 2014	Antibodies and use of ligands binding to the helix-1 region of PrP patented by D-Gen Ltd.; nonexclusively licensed to the Medical Research Council for development of PRN100 to treat prion diseases including CJD and AD; available for licensing	Klyubin, I. *et al. J. Neurosci.*; published online April 30, 2014; doi:10.1523/JNEUROSCI.3526-13.2014 **Contact:** John Collinge, UCL Institute of Neurology, London, U.K. e-mail: j.collinge@prion.ucl.ac.uk **Contact:** Michael J. Rowan, Trinity College Dublin, Dublin, Ireland e-mail: mrowan@tcd.ie